Predicting Treatment Response of Colorectal Cancer Liver Metastases to Conventional Lipiodol-Based Transarterial Chemoembolization Using Diffusion-Weighted MR Imaging: Value of Pretreatment Apparent Diffusion Coefficients (ADC) and ADC Changes Under Therapy

2017 ◽  
Vol 40 (6) ◽  
pp. 852-859 ◽  
Author(s):  
Maximilian Lahrsow ◽  
Moritz H. Albrecht ◽  
Matthew W. Bickford ◽  
Thomas J. Vogl
Keyword(s):  
Colorectal Cancer ◽  
Mr Imaging ◽  
Liver Metastases ◽  
Treatment Response ◽  
Diffusion Coefficients ◽  
Transarterial Chemoembolization ◽  
Colorectal Cancer Liver Metastases ◽  
Apparent Diffusion Coefficients ◽  
Diffusion Weighted ◽  
Apparent Diffusion

Diffusion-weighted MR Imaging of Upper Abdominal Organs: Field Strength and Intervendor Variability of Apparent Diffusion Coefficients

Radiology ◽  
2014 ◽  
Vol 270 (2) ◽  
pp. 454-463 ◽  
Author(s):  
Olivio F. Donati ◽  
Daniel Chong ◽  
Daniel Nanz ◽  
Andreas Boss ◽  
Johannes M. Froehlich ◽  
...  
Keyword(s):  
Mr Imaging ◽  
Field Strength ◽  
Diffusion Coefficients ◽  
Apparent Diffusion Coefficients ◽  
Diffusion Weighted ◽  
Abdominal Organs ◽  
Apparent Diffusion ◽  
Upper Abdominal

Malignant Hepatic Tumors: Short-term Reproducibility of Apparent Diffusion Coefficients with Breath-hold and Respiratory-triggered Diffusion-weighted MR Imaging

Radiology ◽  
2010 ◽  
Vol 255 (3) ◽  
pp. 815-823 ◽  
Author(s):  
So Yeon Kim ◽  
Seung Soo Lee ◽  
Jae Ho Byun ◽  
Seong Ho Park ◽  
Jeong Kon Kim ◽  
...  
Keyword(s):  
Mr Imaging ◽  
Diffusion Coefficients ◽  
Breath Hold ◽  
Hepatic Tumors ◽  
Short Term ◽  
Apparent Diffusion Coefficients ◽  
Diffusion Weighted ◽  
Apparent Diffusion

Salivary Glands and Lesions: Evaluation of Apparent Diffusion Coefficients with Split-Echo Diffusion-weighted MR Imaging—Initial Results

Radiology ◽  
2001 ◽  
Vol 221 (3) ◽  
pp. 837-842 ◽  
Author(s):  
Norio Yoshino ◽  
Ichiro Yamada ◽  
Naoto Ohbayashi ◽  
Eiichi Honda ◽  
Mizue Ida ◽  
...  
Keyword(s):  
Mr Imaging ◽  
Salivary Glands ◽  
Diffusion Coefficients ◽  
Apparent Diffusion Coefficients ◽  
Diffusion Weighted ◽  
Apparent Diffusion ◽  
Initial Results

scholarly journals Irinotecan eluting beads-transarterial chemoembolization using Callispheres® microspheres is an effective and safe approach in treating unresectable colorectal cancer liver metastases

2021 ◽  
Author(s):  
Guangsheng Zhao ◽  
Song Liu ◽  
Yuewei Zhang ◽  
Tong Zhao ◽  
Ruoyu Wang ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Adverse Events ◽  
Liver Metastases ◽  
Treatment Response ◽  
Survival Data ◽  
Transarterial Chemoembolization ◽  
Response Rate ◽  
Objective Response ◽  
Postoperative Treatment ◽  
Colorectal Cancer Liver Metastases

Abstract Background Callispheres® microspheres (CSM) are the first drug-eluting bead (DEB) product developed in China; meanwhile, DEB-transarterial chemoembolization (TACE) with CSM is effective and safe in the treatment of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. However, the data regarding the role of irinotecan-eluting beads-TACE (DEBIRI-TACE) using CSM for colorectal cancer liver metastases (CRLM) treatment is limited. Therefore, the present study aimed to investigate the efficacy and safety of DEBIRI-TACE using CSM in the patients with unresectable CRLM. Methods Totally, 42 unresectable CRLM patients treated with DEBIRI-TACE using CSM were continuously enrolled in this study. Postoperative treatment response (including complete response rate (CR), objective response rate (ORR), and disease control rate (DCR)), survival data (overall survival (OS)), liver function, and adverse events were documented during the follow-up. Results CR, ORR, and DCR were 19.0%, 92.9%, and 100.0%, respectively, at month (M) 1; were 23.8%, 92.9%, and 97.6%, respectively, at M3; then were 14.3%, 78.6%, and 90.5%, respectively at M6. Regarding survival profiles, 1-year OS was 81.0%; 2-year OS was 58.5%; median OS was 25.0 months (95%CI: 19.3–30.7 months). Additionally, ALT and AST experienced an obviously increased trend at 4 days, but a declined trend at 7 days, while ALB and TBIL had no obvious change. No grade 3 or grade 4 adverse event was observed, and main adverse events included fever (95.3%), pain (57.1%), fatigue (50.0%), and nausea/vomiting (42.8%). Conclusion DEBIRI-TACE with CSM achieves high treatment response, acceptable survival benefits, and good toleration in unresectable CRLM treatment.

Sign in / Sign up

Export Citation Format

Share Document